Flag of the European Union EU Clinical Trials Register Help

Clinical trials for History of Virology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: History of Virology. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-001107-20 Sponsor Protocol Number: MDT-637-CP-201 Start Date*: 2013-08-02
    Sponsor Name:MicroDose Therapeutx, Inc., a wholly owned subsidiary of Teva Pharmaceuticals Industries, Ltd.
    Full Title: A Phase 2a Randomised, Double-Blind, Placebo-Controlled Repeat Dose Trial of the Activity of MDT-637 in Healthy Subjects Challenged with RSV-A (Memphis 37b)
    Medical condition: RSV Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10038717 Respiratory syncytial viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000724-35 Sponsor Protocol Number: 216912 Start Date*: 2021-05-11
    Sponsor Name:Vir Biotechnology, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Material in Non-Hospitalized Partici...
    Medical condition: Non-Hospitalized Participants with Mild to Moderate Coronavirus Disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084401 COVID-19 respiratory infection LLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-007100-42 Sponsor Protocol Number: 15581 Start Date*: 2007-01-29
    Sponsor Name:Turku University Hospital
    Full Title: Viral Inception of Asthma: Prospective study from infancy to early school-age.
    Medical condition: First wheezing episode (=acute expiratory breathing difficulty) associated with rhinovirus infection in 3 to 23 -month-old children.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047925 Wheezing expiratory LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000034-36 Sponsor Protocol Number: CHDR1734_CLS003-CO-PR-004 Start Date*: 2018-08-10
    Sponsor Name:Cutanea Life Sciences
    Full Title: A phase 2, randomized, double blind, vehicle controlled, parallel group study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT), comprised of digoxin...
    Medical condition: Actinic keratosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004804-38 Sponsor Protocol Number: 073-202 Start Date*: 2011-12-13
    Sponsor Name:ViroDefense Inc
    Full Title: A Randomized, Blinded, Placebo-Controlled, Poliovirus Challenge Study To Evaluate The Therapeutic Efficacy, Safety, Tolerability And Pharmacokinetics Of Orally Administered V-073 In Healthy Adult V...
    Medical condition: Poliomyelitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10036017 Poliomyelitis viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003849-28 Sponsor Protocol Number: CLS001-CO-PR-014-CHDR1639 Start Date*: 2016-12-15
    Sponsor Name:Cutanea Life Sciences
    Full Title: A randomized, double-blind, placebo-controlled study to assess the pharmacodynamics, safety, tolerability and efficacy of omiganan BID in patients with mild to moderate atopic dermatitis
    Medical condition: Patients with mild to moderate atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10012435 Dermatitis and eczema HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004145-27 Sponsor Protocol Number: Heparc-2002 Start Date*: 2015-06-26
    Sponsor Name:Arrowhead Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination wi...
    Medical condition: Chronic Hepatitis B Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003419-68 Sponsor Protocol Number: HepBTer Start Date*: 2020-12-18
    Sponsor Name:Academic Medical Center (AMC)
    Full Title: From fungus to virus, a phase 2a clinical trial investigating the safety and efficacy of terbinafine in chronic hepatitis B patients
    Medical condition: Chronic hepatitis B infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10052552 Hepatitis B virus LLT
    20.1 10021881 - Infections and infestations 10047450 Viral hepatitis B LLT
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    20.0 100000004848 10019743 Hepatitis B virus (HBV) LLT
    20.0 10021881 - Infections and infestations 10019737 Hepatitis B carrier LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005679-18 Sponsor Protocol Number: GMX04 Start Date*: 2011-12-07
    Sponsor Name:Bio Products Laboratory Limited
    Full Title: A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents
    Medical condition: Primary immunodeficiency diseases
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: Removed from public view
    EudraCT Number: 2014-004751-31 Sponsor Protocol Number: Heparc-2003 Start Date*: 2015-06-26
    Sponsor Name:Arrowhead Research Corporation
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination wi...
    Medical condition: Chronic Hepatitis B Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002845-46 Sponsor Protocol Number: AL-335-604 Start Date*: 2017-02-03
    Sponsor Name:Alios BioPharma, Inc.
    Full Title: A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir, with or without Simeprevir, in Treatment-Naïve Subjects with Genotype ...
    Medical condition: Chronic Hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10076789 Chronic hepatitis C genotype 2 LLT
    20.0 100000004862 10076831 Chronic hepatitis C genotype 3 LLT
    20.0 100000004862 10076786 Chronic hepatitis C genotype 1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003105-18 Sponsor Protocol Number: CHDR1732 Start Date*: 2017-12-13
    Sponsor Name:Centre for Human Drug Research
    Full Title: A randomized, placebo-controlled, evaluator-blinded, study to assess the anti-inflammatory effects of topical erythromycin and clindamycin in patients with inflammatory facial acne
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000496 Acne PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-003106-41 Sponsor Protocol Number: CHDR1733 Start Date*: 2018-09-05
    Sponsor Name:Maruho Co., Ltd.
    Full Title: A phase 2, randomized, vehicle and ketoconazole-controlled, evaluator-blinded, study to explore the efficacy, pharmacodynamics and safety of omiganan 1.75% topical gel BID in patients with mild to ...
    Medical condition: Mild to moderate facial seborrheic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10039788 Seborrheic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000854-73 Sponsor Protocol Number: TCN‐032‐002 Start Date*: 2012-06-21
    Sponsor Name:THERACLONE SCIENCES, INC.
    Full Title: A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TCN-032 (HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST THE M2 PROTEIN OF INFLUENZA A VIRUS) IN SUBJECTS CHALLENGED WITH H3N2 INFLUENZA A VIRUS
    Medical condition: Treatment of severe influenza A virus disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10070215 Influenza A virus test positive PT
    14.1 10021881 - Infections and infestations 10022002 Influenza A virus infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012613-21 Sponsor Protocol Number: VX-950-TiDP24-C219 Start Date*: 2010-06-02
    Sponsor Name:Tibotec BVBA
    Full Title: An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) for subjects from the control group of the VX-950-TiDP2...
    Medical condition: chronic genotype 1 hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    12.0 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DE (Completed) FR (Completed) SE (Completed) PL (Completed) ES (Completed) AT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003358-25 Sponsor Protocol Number: PC10VAC02 Start Date*: 2013-11-25
    Sponsor Name:Genticel
    Full Title: A double-blind, randomised, placebo-controlled, Phase II study to evaluate ProCervix efficacy to clear HPV 16 and HPV 18 infection in women with normal cytology or ASCUS/LSIL
    Medical condition: Women infected by HPV 16 and/or HPV 18 with normal cytology or ASCUS/LSIL
    Disease: Version SOC Term Classification Code Term Level
    17.1 10022891 - Investigations 10064328 Human papilloma virus test positive PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) GB (Completed) FI (Completed) DE (Completed) NL (Ongoing) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001785-95 Sponsor Protocol Number: BTA798-203 Start Date*: 2015-03-16
    Sponsor Name:Biota Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults with Symptomatic Human Rhinovirus Infection.
    Medical condition: Asthma control following presumptive human rhinovirus (HRV) infection in moderate and severe asthma subjects, as measured by the Asthma Control Questionnaire (ACQ-6).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005134-64 Sponsor Protocol Number: AI424-020 Start Date*: 2015-03-13
    Sponsor Name:Bristol-Myers Squibb Company [...]
    1. Bristol-Myers Squibb Company
    2. National Institute of Allergy and Infectious Diseases (NIAID)
    Full Title: Phase I/II Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, ATAZANAVIR, ATV, REYATAZ™) in Combination Regimens in Antiretroviral Therapy (ART)-Naïve and Exper...
    Medical condition: HIV Infections
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004458-33 Sponsor Protocol Number: CMX001-205 Start Date*: 2014-11-27
    Sponsor Name:Chimerix UK Limited
    Full Title: An Open-Label, Multicenter Study of the Safety, Tolerability and Antiviral Activity of Brincidofovir (CMX001) for Treatment of Ebola Virus Disease
    Medical condition: Ebola Virus Disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10014071 Ebola disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000447-40 Sponsor Protocol Number: FARM12FEXH(TESS) Start Date*: 2017-07-12
    Sponsor Name:ASST SANTI PAOLO E CARLO
    Full Title: IMPACT ON BONE MINERAL DENSITY (BMD) OF TDF-SPARING ANTIRETROVIRAL REGIMENS IN HIV-POSITIVE MENOPAUSAL WOMEN AFFECTED BY OSTEOPENIA: THE TENOFOVIR SPARING STRATEGY (TESS) STUDY
    Medical condition: HIV-positive women affected by osteopenia.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10049088 Osteopenia PT
    20.1 100000004862 10008922 Chronic infection with HIV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA